BioTime, Inc. (NYSEMKT:BTX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 – Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
Executive Compensation
On March 29, 2017, our Board of Directors, based on
recommendations of its Compensation Committee, approved the
payment of cash bonuses to certain BioTime executive officers as
shown in the following table.
| Name of Executive | Office | Bonus | ||||
| Michael D. West | Co-Chief Executive Officer | $ | 65,000 | |||
| Aditya Mohanty | Co-Chief Executive Officer | $ | 250,000 | |||
| Russell Skibsted | Chief Financial Officer | $ | 120,000 | |||
The Board of Directors also approved a 3% salary increase for Mr.
Mohanty and Mr. Skibsted, raising their annual salaries to
$515,000 and $370,800, respectively.
About BioTime, Inc. (NYSEMKT:BTX)
BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location. BioTime, Inc. (NYSEMKT:BTX) Recent Trading Information
BioTime, Inc. (NYSEMKT:BTX) closed its last trading session up +0.05 at 3.38 with 387,418 shares trading hands.
